About 77.6K results
Patritumab Deruxtecan Demonstrated Statistically Significant ...
Patritumab Deruxtecan Demonstrated Statistically Significant
Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR …
Patritumab Deruxtecan BLA Submission Receives Complete …
Patritumab Deruxtecan Granted Priority Review in the U.S. for
Patritumab deruxtecan extends PFS vs. chemotherapy in …
Daiichi Sankyo-MSD’s ADC improves survival in NSCLC trial
Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy …
- Some results have been removed